Surgery – Diagnostic testing – Detecting nuclear – electromagnetic – or ultrasonic radiation
Reexamination Certificate
2000-08-07
2003-01-21
Shaw, Shawna J (Department: 3737)
Surgery
Diagnostic testing
Detecting nuclear, electromagnetic, or ultrasonic radiation
C600S478000, C600S160000
Reexamination Certificate
active
06510338
ABSTRACT:
DESCRIPTION
FIELD OF THE INVENTION
The present invention relates to a method of fluorescence diagnosis of tissue, particularly by endoscopy, as well as devices for performing fluorescence diagnoses. Such devices are also referred to as photodynamic diagnosis systems (PDD systems).
These methods or devices, respectively, are employed for the “in vivo” diagnosis operating on a reaction induced by light in biologic tissue by an endogenic or exogenic photo sensitising agent; such methods and devices can be employed in particular for the (early) diagnosis of tumours and for tumour localisation.
Fundamentals
For triggering a light-induced reaction in biologic systems a photo sensitising agent (also referred to as photo sensitizer) can be administered to the patient in a concentration of a few mg/kg of the body weight. Typical photo sensitizers display a basic hemato-porphyrin structure such as the substances Photofrin and Photosan-3. Another photo sensitizer that is frequently used in urology and dermatology is delta amino levulinic acid (ALA).
The hemato-porphyrin derivatives are administered into the veins whereas delta amino levulinic acid is suitable for local application, which means that it is injected as a solution into the urinary bladder. These substances accumulate in tumour tissues in a concentration increased by 2 to 10 times. This selective accumulation in the tumour tissue constitutes the decisive basis for diagnosing tumours by photo dynamic diagnosis and for the photo dynamic tumour therapy.
For diagnosis, the tissue to be examined is exposed to ultraviolet irradiation for roughly 2 to 12 hours after administration of the photo sensitizer. The photo-sensitising agents present in the tumour tissue in an increased concentration are stimulated by this light and present thereafter a typical red fluorescence by which the tumour can be localised.
In addition to fluorescence—induced by a photo sensitizer accumulated in the tissue—also the so-called auto fluorescence can be triggered in the tissue, which is brought about by so-called fluorophores, i.e. endogenic fluorescent substances.
The bio-physical sequence of light-induced reaction can be assumed to develop as follows:
The photo sensitizer accumulated in the tissue is caused to switch over into an excited state by the absorption of a light quantum carrying a defined energy, which is emitted by the respective light source. Exposure to violet light as part of the photo dynamic diagnosis causes the emission of a fluorescent radiation when the sensitizer returns into the basic state.
In the case of photo dynamic therapy in combination with irradiation with red light at a high power density the transition takes place from the excited state into a meta stable interim state from which the energy that is discharged by the return into the basic state is transferred to molecular oxygen which receives this energy and forms thereby stimulated singlet oxygen. The aggressive singlet oxygen destroys cell structures in the respective tissue by photo oxidation. This cellular damage, together with a simultaneously occurring collapse of the tumour vessel system, results in a complete destruction of the tumour (photo toxic effect).
Prior Art
A method and a device which the wording of the independent Patent Claims starts out from is known from the document WO 97/11636 or the pamphlet “Endoworld D-Light” by Karl Storz GmbH & Co.
PDD systems of another general type are disclosed in the German Patent DE-A41 33 493 or the U.S. Pat. No. 5,701,903. Moreover, the realisation of an endoscopic photo dynamic diagnosis and therapy by means of a device has been proposed wherein a laser, specifically a krypton ion laser, is employed as light source emitting a wavelength of roughly 420 nm and producing a power of more than 200 mWatt. The light of this laser is passed via an optical quartz guide having a numerically small aperture through an endoscope to the locations in the human body which are to be irradiated.
For an explanation of all particulars not described here in details explicit reference is made, by the way, to the aforementioned prior art documents.
The “D-Light system” described in the aforementioned pamphlet has been designed for application with 5-amino levulinic acid (5-ALA) as photo sensitizer also for the induced fluorescence analysis.
For such an application the device comprises an illuminating system including at least one illuminating light source which emits a stimulating light over a wide bandwidth for stimulating the fluorescence of the photo sensitizer. The light is coupled into the optical guide of an endoscope including a lens with an object field illuminated by the stimulating light, and an image transmitting system which transmits the image from the lens to the proximal end of the endoscope. Moreover, a filter system is provided that comprises stimulating filters in the light path between the illuminating system and the tissue to be examined, as well as observation filters along the path of the observation beams, as formed by the lens and the image transmitting system. The characteristics of the stimulating filter in transmission are so selected that the spectral distribution of the stimulating light is matched with the fluorescence stimulating spectrum of the tissue to be examined. The transmission characteristics of the observation filter are so selected that, on the one hand, the fluorescent light is not outshone by the stimulating light reflected on the tissue directly but that, on the other hand, the area under examination can also be observed by the examining physician also due to the directly reflected stimulating light.
The known PDD system “D-Light” has been applied in urology, neuro surgery and other branches for photo dynamic diagnosis with great success.
On the other hand, lung cancer is the most frequently occurring cause of death due to cancer. Attempts have been made to administer the photo sensitizer 5-ALA by inhalation. This furnishes good results only partly. What is particularly problematic is the reproducibility of this form of administration. In accordance with the invention, now the fact has been detected that this problem can be overcome by the simultaneous detection of auto fluorescence.
All the methods in which fluorescence is induced by means of a photo sensitizer suffer from the further advantage that preliminarily the photo sensitizer(s) must be administered for producing its or their effects only after a certain time—within the range from several minutes to a couple of hours—which, on the other hand, is (are) bleached out in the course of the examination and might also be intolerable under certain conditions.
For this reason methods have been proposed which utilise only the auto fluorescence of tissue. Appropriate systems are disclosed, for instance, in the European Patent EP-B-0 512 965, the U.S. Pat. No. 5,507,287, the U.S. Pat. No. 5,413,108, or the German Patent DE-A-196 461 776. What is a disadvantage in these methods is the aspect that they employ merely the auto fluorescence effect for diagnosis—even though they are comparatively expensive—and hence furnish a comparatively low-contrast image in many cases.
All the aforementioned systems share the common feature that the filter systems provided in the path of the illuminating beams or the observation beams, respectively, are matched with the type of the respective fluorescence to be stimulated. As a consequence, it is necessary to change the filters when fluorescence is stimulated by means of another photo sensitizer or when a change is to be made from fluorescence induced by a photo sensitizer or auto fluorescence.
BRIEF DESCRIPTION OF THE INVENTION
The present invention is based on the problem of providing a method of endoscopic fluorescence diagnosis of tissue, which permits the execution of different diagnostic procedures—i.e. diagnostic procedure operating on different photo sensitizers and/or of induced and endogenic fluorescence; moreover, the inventive device should be so designed that the expenditure incurred by a conversion of the
Erhardt André
Irion Klaus M.
Pichler Josef Peter
Stepp Herbert
Karl Storz GmbH & Co. KG
Shaw Shawna J
St. Onge Steward Johnston & Reens LLC
LandOfFree
Method of and devices for fluorescence diagnosis of tissue,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of and devices for fluorescence diagnosis of tissue,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of and devices for fluorescence diagnosis of tissue,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3026291